Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
1.
Int J Hematol ; 119(3): 338-341, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38294639

ABSTRACT

BACKGROUND: Development of secondary tumor after CART treatment is not well investigated. We report a pediatric B-cell acute lymphoblastic leukemia (B-ALL) patient who developed histiocytic sarcoma shortly after CART therapy. CASE REPORT: A 9-year-old boy diagnosed with relapsed B-ALL presenting the KRAS A146T mutation received autologous mouse-derived CD19 and CD22 chimeric antigen receptor T-cell therapy at our center (Chinese Clinical Trial Registry: ChiCTR2000032211). Thirty days post-CART therapy, the bone marrow showed complete remission. At 85 days post-CART therapy, the boy presented with fever and chills. An abdominal CT scan showed massive hepatomegaly with multiple low-density lesions in the liver. At 130 days post-CART therapy, a bone marrow smear showed abnormal proliferation of macrophages, some of which exhibited phagocytosis. On day 136 post-CART therapy, laparoscopic liver biopsy was performed, revealing multiple yellow-white lesions on the surface of the liver. Microscopically, multifocal lesions were observed, predominantly composed of cells with abundant cytoplasm. Immunohistochemical staining indicated histiocytic origin. Based on the immunohistochemical results, histiocytic sarcoma was diagnosed. The same cytogenetic markers were identified in histiocytic sarcoma. CONCLUSION: Our case illustrates a rare complication after CART therapy. The diagnosis and treatment of histiocytic sarcoma pose many challenges.


Subject(s)
Histiocytic Sarcoma , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma , Male , Humans , Child , Animals , Mice , Immunotherapy, Adoptive/methods , Histiocytic Sarcoma/etiology , Histiocytic Sarcoma/therapy , Antigens, CD19 , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/therapy , Bone Marrow/pathology
3.
Int J Surg Pathol ; 29(3): 321-326, 2021 May.
Article in English | MEDLINE | ID: mdl-32677548

ABSTRACT

Genetically driven tissue destruction followed by remodeling in adult polycystic kidney disease (APKD) raises the possibility of malignant transformation. Renal cell carcinoma (RCC) associated with APKD has been frequently reported in the literature; however, only a few cases of nonepithelial neoplasms arising in APKD have been described so far. Histiocytic sarcoma (HS) is a lymphohematopoietic malignant neoplasm that accounts for less than 1% of hematologic malignancies. In this article, we describe a case of primary HS occurring in a 61-year-old man with end-stage renal disease secondary to APKD. This is the first reported case of primary HS in the setting of APKD. The aberrant h-caldesmon expression seen in this case is another novel finding that has previously not been described. This case highlights the importance of morphology in guiding diagnostic workup and reiterates the necessity of maintaining a high index of suspicion for neoplastic entities in APKD.


Subject(s)
Histiocytic Sarcoma/diagnosis , Kidney Neoplasms/diagnosis , Kidney/pathology , Polycystic Kidney, Autosomal Dominant/complications , Fatal Outcome , Histiocytic Sarcoma/etiology , Histiocytic Sarcoma/pathology , Humans , Kidney/diagnostic imaging , Kidney Neoplasms/etiology , Kidney Neoplasms/pathology , Male , Middle Aged , Nephrectomy , Polycystic Kidney, Autosomal Dominant/pathology , Tomography, X-Ray Computed
4.
Res Vet Sci ; 124: 57-60, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30852355

ABSTRACT

Canine histiocytic sarcoma (HS) is an aggressive tumor type originating from dendritic cells or macrophages. We previously reported high incidence of the two-base (AT) insertion mutation (insAT) in the tumor protein p53 (TP53) gene in dogs with HS, and the aim of this study was to investigate the clinical significance of insAT in canine HS. The present study established a sensitive digital PCR-based assay for detecting insAT and examined its associations with clinical variables and survival time. The mutation was detected in 26 of 64 dogs (41%), and the mean mutant allele frequency was 1.9% (range, 0.014-35%), indicating that not all tumor cells harbor insAT. The incidence of insAT was significantly higher in dogs with metastatic lesions than in those without metastatic lesions. However, the existence of insAT was not associated with survival time or response to chemotherapy with lomustine or nimustine. This study suggested that HS cells might acquire insAT in the TP53 gene during development of metastasis, but insAT was not a prognostic factor in canine HS. Further studies are needed to investigate the contribution of insAT to the development of metastatic lesions of canine HS.


Subject(s)
Dog Diseases/genetics , Histiocytic Sarcoma/veterinary , Mutagenesis, Insertional/genetics , Tumor Suppressor Protein p53/genetics , Animals , Dog Diseases/etiology , Dogs , Female , Genes, p53 , Histiocytic Sarcoma/etiology , Histiocytic Sarcoma/genetics , Male , Tumor Suppressor Protein p53/metabolism
5.
Autops. Case Rep ; 8(1): e2018001, Jan.-Mar. 2018. tab, ilus
Article in English | LILACS | ID: biblio-905418

ABSTRACT

Histiocytic sarcoma (HS) is a rare malignant neoplasia of hematopoietic origin and unknown etiology. We studied three patients with histiocytic sarcoma reviewing the morphological and immunohistochemical aspects. We evaluated in particular, if apoptosis may be unbalanced in this disease. All cases have morphological and immunohistochemical features consistent with the diagnosis of histiocytic sarcoma. The markers CD163, CD68, vimentin, lysozyme, and S-100 were positive in all cases. Similarly, the three samples were positive for Fas-ligand and Caspase-3. It is well-known that neoplasms may induce increased levels of Fas-ligand with the blockade of the apoptosis process. In the context of HS, the increased Fas-ligand expression represents a new area for research. Indeed, it is linked to proinflammatory stimulus and, maybe with the association of an infection.


Subject(s)
Humans , Male , Female , Adult , Aged , Histiocytic Sarcoma/etiology , Apoptosis , Caspase 3 , Fas Ligand Protein , Histiocytic Sarcoma/diagnosis , Immunohistochemistry
6.
Vet Comp Oncol ; 16(1): E83-E88, 2018 Mar.
Article in English | MEDLINE | ID: mdl-28836371

ABSTRACT

Periarticular histiocytic sarcoma (PAHS) is the most common synovial tumour in dogs and is characterized by aggressive local disease with a high rate of distant metastasis. Previously, an association between PAHS and prior joint disease has been demonstrated in the Bernese Mountain Dog breed and suggested in the Rottweiler. We hypothesized that this association would be present in other breeds and investigated this via a retrospective, case-controlled analysis. Cases were dogs diagnosed with PAHS of the stifle or elbow. Controls were age, breed and sex-matched dogs without a diagnosis of histiocytic sarcoma. Diagnosis of prior joint disease was determined based on review of medical records and direct veterinarian and owner communications. Data were evaluated using logistic regression, 2-sampled t tests, and chi-squared analysis. Our study population consisted of 28 cases and 46 controls, including Flat-Coated, Golden and Labrador Retrievers, Rottweilers, English Bulldogs, Shih Tzus, Australian Shepherds, Staffordshire Terriers and mixed breed dogs. Dogs with PAHS were more likely to have prior joint disease in the tumour-affected joint compared with the control population (odds ratio [OR] = 13.42, P < .0001, 95% confidence interval [CI] = 4.33-48.63). A total of 88.2% of dogs with stifle PAHS had prior joint disease in their tumour-affected joint, most commonly cranial cruciate ligament rupture. This study confirms that the previously noted association between prior joint disease and PAHS in Bernese Mountain Dogs also applies to other breeds. Additional studies are needed to further investigate for a causal relationship.


Subject(s)
Dog Diseases/etiology , Histiocytic Sarcoma/veterinary , Joint Diseases/veterinary , Animals , Case-Control Studies , Dogs , Female , Histiocytic Sarcoma/etiology , Joint Diseases/complications , Male , Risk Factors
7.
Nat Commun ; 7: 11589, 2016 05 20.
Article in English | MEDLINE | ID: mdl-27199251

ABSTRACT

Resistance to the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely to mutations in BTK and related pathway molecules. Using whole-exome and deep-targeted sequencing, we dissect evolution of ibrutinib resistance in serial samples from five chronic lymphocytic leukaemia patients. In two patients, we detect BTK-C481S mutation or multiple PLCG2 mutations. The other three patients exhibit an expansion of clones harbouring del(8p) with additional driver mutations (EP300, MLL2 and EIF2A), with one patient developing trans-differentiation into CD19-negative histiocytic sarcoma. Using droplet-microfluidic technology and growth kinetic analyses, we demonstrate the presence of ibrutinib-resistant subclones and estimate subclone size before treatment initiation. Haploinsufficiency of TRAIL-R, a consequence of del(8p), results in TRAIL insensitivity, which may contribute to ibrutinib resistance. These findings demonstrate that the ibrutinib therapy favours selection and expansion of rare subclones already present before ibrutinib treatment, and provide insight into the heterogeneity of genetic changes associated with ibrutinib resistance.


Subject(s)
Clonal Evolution , Drug Resistance, Neoplasm/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Neoplasm Recurrence, Local/genetics , Protein-Tyrosine Kinases/genetics , Pyrazoles/therapeutic use , Pyrimidines/therapeutic use , Adenine/analogs & derivatives , Adult , Agammaglobulinaemia Tyrosine Kinase , Aged, 80 and over , Apoptosis , Cell Transdifferentiation , Female , Histiocytic Sarcoma/etiology , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Male , Middle Aged , Mutation , Piperidines , Protein-Tyrosine Kinases/antagonists & inhibitors , Pyrazoles/pharmacology , Pyrimidines/pharmacology , Selection, Genetic
8.
Eur J Haematol ; 97(1): 9-16, 2016 Jul.
Article in English | MEDLINE | ID: mdl-26990812

ABSTRACT

Histiocytic sarcoma (HS) is an extremely rare non-Langerhans cell disorder with an aggressive course and limited treatment options. Recent advances in molecular/genetic sequencing have suggested a common clonal origin between various hematolymphoid disorders and cases of secondary HS. Deriving conclusions from previously reported cases of HS arising secondarily to certain hematolymphoid disorders, here we have tried to provide insight into the mechanisms influencing this evolution. We also discuss a clinical case of a 72-year-old man with a diagnosis of chronic myeloid leukemia (CML), presenting subsequently with a heterogeneous liver mass positive with a diagnosis of HS. The liver mass showed a retained BCR-ABL1 translocation suggesting clonality between the CML and HS. As seen in our case and other reported cases of HS derived secondarily, the concurrent expression of immunoglobulin heavy (IGH)-/light-chain rearrangements or cytogenetic markers common to the primary malignancy suggests an evolutionary mechanism involving lineage switching that could potentially be influenced by genetic or epigenetic cues which may occur at the level of a progenitor or the malignant cell itself.


Subject(s)
Histiocytic Sarcoma/diagnosis , Histiocytic Sarcoma/etiology , Histiocytic Sarcoma/therapy , Neoplasms, Second Primary/diagnosis , Neoplasms, Second Primary/etiology , Neoplasms, Second Primary/therapy , Aged , Biopsy , Bone Marrow/pathology , Cellular Reprogramming , Diagnosis, Differential , Epigenesis, Genetic , High-Throughput Nucleotide Sequencing , Histiocytic Sarcoma/epidemiology , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Male , Mutation , Neoplasms, Second Primary/epidemiology
9.
Medicine (Baltimore) ; 95(2): e2515, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26765473

ABSTRACT

Mediastinal nonseminomatous germ cell tumor (MNSGCT)-associated histiocytic proliferations are rare and rapidly fatal disorders. Standard treatment modalities have yet to be established.We report a case of MNSGCT-associated hemophagocytic syndrome that evolved into malignant histiocytosis/disseminated histiocytic sarcoma (MH/HS), which was initially treated with intravenous immunoglobulin, corticosteroids, and cyclosporine. Then, thalidomide plus cyclophosphamide, adriamycin, oncovin, prednisolone chemotherapy followed by alemtuzumab-containing reduced-intensity allogeneic peripheral blood stem cell transplantation (PBSCT) was used as salvage therapy.The severe constitutional symptoms and pancytopenia resolved shortly after thalidomide with cyclophosphamide, adriamycin, oncovin, prednisolone. After PBSCT, the patient developed steroid-dependent skin graft-versus-host disease, but maintained a functional life for 1.5 years. Rapid resolution of chronic graft-versus-host disease preceded the fulminant recurrence of hemophagocytic syndrome and MH/HS.Thalidomide plus chemotherapy followed by alemtuzumab-containing reduced intensity allogeneic PBSCT is effective in allaying MNSGCT-associated histiocytic disorders, but does not prevent eventual relapse. However, further posttransplant immune modulation should be developed to completely eradicate the residual MH/HS cells.


Subject(s)
Antineoplastic Agents/therapeutic use , Histiocytic Sarcoma/drug therapy , Mediastinal Neoplasms/complications , Neoplasms, Germ Cell and Embryonal/complications , Peripheral Blood Stem Cell Transplantation , Alemtuzumab , Antibodies, Monoclonal, Humanized/therapeutic use , Fatal Outcome , Histiocytic Sarcoma/etiology , Humans , Immunosuppressive Agents/therapeutic use , Male , Mediastinal Neoplasms/drug therapy , Neoplasms, Germ Cell and Embryonal/drug therapy , Thalidomide/therapeutic use , Transplantation, Homologous , Young Adult
10.
J Neuropathol Exp Neurol ; 74(12): 1120-6, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26574666

ABSTRACT

Histiocytic sarcomas (HSs) are rare malignant neoplasms derived from histiocytes that may be associated with other hematolymphoid neoplasms. Histiocytic sarcomas rarely occur in the CNS and have not previously been reported in conjunction with prior B-cell lymphoblastic leukemia. We report the case of a 23-year-old man who presented with primary CNS HS 7 years after achieving remission for precursor B-cell acute lymphoblastic leukemia (B-ALL). Molecular studies revealed clonal immunoglobulin heavy-chain (IGH) gene rearrangement within the HS, suggesting linkage to his previous B-ALL. Previously reported post-ALL HSs show a strong predilection for young males (male-to-female ratio, 20:1), whereas cases of primary CNS HS without previous ALL affected older adults with balanced sex predilection. The patient's survival at 60 months exceeds expectations when compared with that of other reported cases of de novo primary CNS HS (n = 18) and post-ALL HS at all sites (n = 19). In addition, we discuss the potential relationship between B-ALL and HS posed by other authors.


Subject(s)
Central Nervous System Neoplasms/pathology , Histiocytic Sarcoma/etiology , Histiocytic Sarcoma/pathology , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/complications , Antigens, CD/metabolism , Humans , Immunoglobulin Heavy Chains/genetics , Male , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/pathology , Young Adult
11.
Res Vet Sci ; 99: 137-44, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25744435

ABSTRACT

Histiocytic sarcoma (HS) in dogs exhibits aggressive clinical and biological behavior. Currently, no effective treatments are available for dogs with HS. Survivin, a member of a family of apoptosis protein inhibitors, could serve as a potential therapeutic target in several canine cancers. Sepantronium bromide (YM155) has recently been established as a novel survivin-targeting agent. The aim of this study was to use YM155 as a tool for evaluating survivin-targeted therapies against dogs with HS, and to investigate how YM155 treatment affects antitumor and chemotherapeutic efficacies in murine xenograft models using canine HS cells. The results showed that in HS cells with lomustine (CCNU) resistance, YM155 treatment suppressed both the cell-growth potential and cell resistance to CCNU, which essentially increases the chemotherapy efficacy in the murine models. The evidence presented here supports the favorable preclinical evaluation that survivin-targeted therapies might be effective against HS in dogs.


Subject(s)
Antineoplastic Agents/therapeutic use , Dog Diseases/drug therapy , Histiocytic Sarcoma/veterinary , Imidazoles/therapeutic use , Inhibitor of Apoptosis Proteins/antagonists & inhibitors , Naphthoquinones/therapeutic use , Repressor Proteins/antagonists & inhibitors , Animals , Cell Line, Tumor , Dog Diseases/etiology , Dogs , Histiocytic Sarcoma/drug therapy , Histiocytic Sarcoma/etiology , Mice , Models, Animal , Survivin
12.
Vet J ; 198(3): 678-83, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24231621

ABSTRACT

Bernese mountain dogs and Flat-coated retrievers are predisposed to hereditary oncological diseases. Since 1986 several authors have reported a high prevalence of tumours in both breeds, especially malignant histiocytosis/histiocytic sarcoma, which has a negative influence on life expectancy. However, many earlier reports included relatively low numbers of dogs, distributed over a small number of broad categories, often using outdated disease criteria. The aim of this study was to provide new data on causes of death, and the relative role of tumours, especially histiocytic sarcoma, collected and verified in a large number of dogs of both breeds in co-operation with dog owners and veterinarians. The study demonstrates that the death of at least 55.1% of Bernese mountain dogs and 63.8% of Flat-coated retrievers is associated with malignant tumours. In addition, it appears that over 1/7 of all Bernese mountain dogs and Flat-coated retrievers die because of histiocytic sarcoma. This emphasises the need for further research on tumours, especially histiocytic sarcoma.


Subject(s)
Dog Diseases/epidemiology , Histiocytic Sarcoma/veterinary , Animals , Cause of Death , Dog Diseases/etiology , Dog Diseases/genetics , Dogs , Female , Histiocytic Sarcoma/epidemiology , Histiocytic Sarcoma/etiology , Histiocytic Sarcoma/genetics , Life Expectancy , Male , Netherlands/epidemiology
13.
J Vet Intern Med ; 27(2): 293-9, 2013.
Article in English | MEDLINE | ID: mdl-23458888

ABSTRACT

BACKGROUND: Peri-articular histiocytic sarcoma (PAHS) occurs in dogs, including Bernese Mountain Dogs (BMD). An etiologic relationship with previous joint disease has not been documented. HYPOTHESIS: Peri-articular histiocytic sarcoma in BMD will be more frequently encountered around previously diseased joints compared with normal joints. ANIMALS: 920 European BMD. METHODS: A retrospective study, in which data were obtained through an Internet questionnaire and from 2 veterinary pathology laboratories. Archived samples of hematoxylin-eosin (H&E) staining diagnosed PAHS and synovial cell sarcoma (SCS) were immunolabeled with CD18 and pancytokeratin. Descriptive, comparative, and actuarial statistics comprise the data analysis. RESULTS: All primary synovial tumors were identified as PAHS based on their morphology, positive CD18, and negative pancytokeratin labeling. Joint disease was diagnosed in 226 BMD, of which 15 developed PAHS in a previously diseased joint and 3 in a nondiseased joint. Of the remaining 694 BMD without joint disease, 9 developed PAHS. The odds ratio for a dog with previous joint disease developing PAHS is calculated as 5.4 (95% CI: 2.3-12.5; P < .0001) compared with no previous joint problem. A significant association between previous joint disease and PAHS in the same joint was demonstrated for the left elbow (P = .016), right elbow (P = .006), right shoulder (P = .047), left and right stifle (P < .001), and left carpal joint (P = .010). CONCLUSIONS AND CLINICAL IMPORTANCE: The results of this study suggest a relation between previous joint disease and the development of PAHS in the same joint of European BMD. Owners of BMD should monitor dogs for peri-articular swellings, particularly around previously diseased joints.


Subject(s)
Dog Diseases/pathology , Histiocytic Sarcoma/veterinary , Joint Capsule/pathology , Joint Diseases/veterinary , Animals , Chi-Square Distribution , Dogs , Female , Histiocytic Sarcoma/etiology , Histiocytic Sarcoma/pathology , Histocytochemistry/veterinary , Joint Diseases/pathology , Male , Retrospective Studies
14.
J Pediatr Hematol Oncol ; 34(6): 480-3, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22810753

ABSTRACT

Aggressive histiocytic lesions are uncommon in the pediatric population. These neoplasms occur in isolation or after therapy for other types of hematopoietic malignancy such as T-cell acute lymphoblastic leukemia. The etiology of these lesions is poorly understood, and no definitive standard of care has been established for patients with these diagnoses. Here, we report the success of thalidomide treatment for 2 subtypes of histiocytic proliferation--metastatic histiocytic sarcoma and extracutaneous juvenile xanthogranuloma--in pediatric patients. Our findings highlight the importance of considering thalidomide therapy in this unique and difficult to treat patient population.


Subject(s)
Histiocytic Sarcoma/drug therapy , Immunosuppressive Agents/therapeutic use , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Thalidomide/therapeutic use , Xanthogranuloma, Juvenile/drug therapy , Adolescent , Child , Female , Histiocytic Sarcoma/epidemiology , Histiocytic Sarcoma/etiology , Humans , Michigan/epidemiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Prognosis , Xanthogranuloma, Juvenile/epidemiology , Xanthogranuloma, Juvenile/etiology
16.
Int J Hematol ; 92(1): 168-73, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20535595

ABSTRACT

A 70-year-old male was admitted because of back pain due to peri-vertebral tumors. The histologic picture of a needle-biopsied tumor specimen showed pleomorphic large cell infiltration into the collagen fibers. On immunohistochemistry, these abnormal cells were positive for CD68, CD163 and lysozyme but negative for CD1a, 21, 30, and S100. Flow cytometric analysis also demonstrated that these cells were positive for CD13, 14, 38, 45, 56, and HLA-DR. A bone marrow aspirate showed the marked infiltration of abnormal large cells with the same surface antigens as described above. A diagnosis of HS was made. He showed monocytosis in the peripheral blood of more than 1.0 x 10(9)/L from presentation. The karyotype of bone marrow cells was 46,XY,+8. Fluorescent in situ hybridization (FISH) analysis with a probe for chromosome no. 8 showed that all these monocytes carried +8, indicating that he had another disorder of chronic myelomonocytic leukemia (CMML). FISH analysis with a probe for chromosome no. 12 demonstrated that the abnormal large cells in the bone marrow were all tetraploid, while analysis with the chromosome no. 8 probe showed more than 8 signals per cell, indicating that HS cells carried octasomy to decasomy of chromosome no. 8. These findings strongly suggest that HS in the present patient originated from underlying CMML.


Subject(s)
Histiocytic Sarcoma/diagnosis , Leukemia, Myelomonocytic, Chronic/complications , Aged , Chromosomes, Human, Pair 8 , Histiocytic Sarcoma/etiology , Histiocytic Sarcoma/pathology , Humans , Immunophenotyping , Leukemia, Myelomonocytic, Chronic/pathology , Male , Polyploidy
17.
J Clin Neurosci ; 16(12): 1641-3, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19766005

ABSTRACT

This report presents a 70-year-old male who presented with a rare malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma. To our knowledge, malignant fibrous histiocytosis caused by proton therapy has not been reported, therefore the clinical features of this complication are described and previous cases are reviewed.


Subject(s)
Histiocytic Sarcoma/etiology , Radiotherapy, High-Energy/adverse effects , Aged , Astrocytoma/radiotherapy , Brain Neoplasms/radiotherapy , Histiocytic Sarcoma/diagnosis , Humans , Magnetic Resonance Imaging/methods , Male
18.
Tumori ; 90(6): 622-4, 2004.
Article in English | MEDLINE | ID: mdl-15762368

ABSTRACT

BACKGROUND: The development of secondary soft tissue sarcomas after chemo-radiotherapy is a rare and little known event, but its frequency is increasing. PATIENTS AND METHODS: We report two cases of secondary soft tissue sarcomas. The first is the case of a 51-year-old woman treated for Hodgkin's disease with chemotherapy and radiotherapy 15 years before she developed a high-grade malignant pleural sarcoma. The patient had no history of asbestos exposure. The second is the case of a 64-year-old woman with a giant cell malignant histiocytoma secondary to colorectal cancer treated with surgery and radiotherapy nine years before. The patients were not eligible for surgery or radiotherapy. Both were treated with chemotherapy (ifosfamide and epirubicin) without any relevant secondary effects; however, the response to therapy was poor. CONCLUSIONS: The causes of secondary malignancies are multifactorial, but radiation therapy and chemotherapy are certainly implicated in the development of post-therapy neoplasms that are difficult to treat.


Subject(s)
Histiocytic Sarcoma/etiology , Neoplasms, Radiation-Induced/etiology , Neoplasms, Second Primary/etiology , Pleural Neoplasms/etiology , Sarcoma/etiology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemotherapy, Adjuvant/adverse effects , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/radiotherapy , Female , Histiocytic Sarcoma/drug therapy , Hodgkin Disease/drug therapy , Hodgkin Disease/radiotherapy , Humans , Middle Aged , Neoplasms, Radiation-Induced/drug therapy , Neoplasms, Second Primary/drug therapy , Pleural Neoplasms/drug therapy , Radiotherapy, Adjuvant/adverse effects , Sarcoma/drug therapy
20.
Oral Surg Oral Med Oral Pathol ; 78(4): 476-9, 1994 Oct.
Article in English | MEDLINE | ID: mdl-7800380

ABSTRACT

We report the case of a patient in whom oral squamous cell carcinoma and a fatal reactive form of histiocytosis were simultaneously manifested. Our conclusions indicate that such a hematophagocytic syndrome may occur in the setting of oral squamous cell carcinoma as previously described in other malignancies.


Subject(s)
Carcinoma, Squamous Cell/pathology , Histiocytic Sarcoma/pathology , Mouth Neoplasms/pathology , Neoplasms, Multiple Primary/pathology , Neoplasms, Radiation-Induced/etiology , Aged , Carcinoma, Squamous Cell/radiotherapy , Fatal Outcome , Histiocytic Sarcoma/etiology , Humans , Male , Mouth Floor/pathology , Mouth Neoplasms/radiotherapy , Radiotherapy, Adjuvant/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...